William Blair & Company
NBIX icon

William Blair & Company’s Neurocrine Biosciences NBIX Stock Holding History

William Blair & Company’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.68M Buy
51,511
+47,566
+1,206% +$7.06M 0.02% 394
2026
Q1 		$520K Sell
3,945
-555
-12% -$73.6K ﹤0.01% 1136
2025
Q4 		$638K Buy
4,500
+39
+0.9% +$5.65K ﹤0.01% 1062
2025
Q3 		$626K Sell
4,461
-203
-4% -$27.5K ﹤0.01% 1043
2025
Q2 		$586K Sell
4,664
-1,550
-25% -$178K ﹤0.01% 1048
2025
Q1 		$687K Sell
6,214
-242
-4% -$30.7K ﹤0.01% 990
2024
Q4 		$881K Buy
6,456
+12
+0.2% +$1.48K ﹤0.01% 940
2024
Q3 		$742K Sell
6,444
-1,383
-18% -$190K ﹤0.01% 997
2024
Q2 		$1.08M Sell
7,827
-772
-9% -$106K ﹤0.01% 847
2024
Q1 		$1.19M Buy
8,599
+481
+6% +$65.7K ﹤0.01% 814
2023
Q4 		$1.07M Sell
8,118
-562
-6% -$64.7K ﹤0.01% 836
2023
Q3 		$977K Sell
8,680
-5,585
-39% -$588K ﹤0.01% 845
2023
Q2 		$1.35M Sell
14,265
-297,485
-95% -$29.1M ﹤0.01% 756
2023
Q1 		$31.6M Buy
311,750
+237,264
+319% +$24.7M 0.13% 150
2022
Q4 		$8.9M Buy
74,486
+63,184
+559% +$7.4M 0.04% 313
2022
Q3 		$1.2M Buy
11,302
+170
+2% +$17.2K 0.01% 760
2022
Q2 		$1.08M Buy
11,132
+602
+6% +$55.6K ﹤0.01% 823
2022
Q1 		$987K Sell
10,530
-4,807
-31% -$407K ﹤0.01% 927
2021
Q4 		$1.31M Sell
15,337
-4,740
-24% -$436K ﹤0.01% 863
2021
Q3 		$1.93M Buy
20,077
+162
+0.8% +$15.3K 0.01% 715
2021
Q2 		$1.94M Buy
19,915
+248
+1% +$23.8K 0.01% 714
2021
Q1 		$1.91M Sell
19,667
-10,562
-35% -$1.11M 0.01% 706
2020
Q4 		$2.9M Buy
+30,229
New +$2.92M 0.01% 556

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

William Blair & Company's NBIX Position: Q2 2026 in Review

William Blair & Company increased its Neurocrine Biosciences (NBIX) stake by 1,206% in Q2 2026, buying an estimated $7.06M and bringing the position to 51,511 shares worth $8.68M. The position accounts for 0.02% of the portfolio, ranked #394.

William Blair & Company first reported a position in NBIX in Q4 2020 and has held it in 23 quarters since. The position peaked at $31.6M in Q1 2023. 781 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • William Blair & Company held 51,511 shares of Neurocrine Biosciences worth $8.68M as of Q2 2026.
  • William Blair & Company bought 47,566 Neurocrine Biosciences shares in Q2 2026, an estimated $7.06M.
  • Neurocrine Biosciences made up 0.02% of William Blair & Company's portfolio in Q2 2026, its #394 holding.
  • William Blair & Company first reported a position in Neurocrine Biosciences in Q4 2020 and has held it in 23 quarters since.
  • William Blair & Company's Neurocrine Biosciences position peaked at $31.6M in Q1 2023.
  • 781 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on William Blair & Company's 13F filing for Q2 2026, filed 11 Aug 2026.